Recursion Pharmaceuticals, Inc. (RXRX)
4.12
+0.05
(+1.23%)
USD |
NASDAQ |
Oct 02, 16:00
4.12
0.00 (0.00%)
After-Hours: 20:00
Recursion Pharmaceuticals Price to Book Value : 2.405 for Oct. 2, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.405 |
| October 01, 2026 | 2.376 |
| September 30, 2026 | 2.411 |
| September 29, 2026 | 2.352 |
| September 28, 2026 | 2.160 |
| September 25, 2026 | 2.183 |
| September 24, 2026 | 2.271 |
| September 23, 2026 | 2.160 |
| September 22, 2026 | 2.364 |
| September 21, 2026 | 2.317 |
| September 18, 2026 | 2.236 |
| September 17, 2026 | 2.066 |
| September 16, 2026 | 1.862 |
| September 15, 2026 | 1.891 |
| September 14, 2026 | 1.990 |
| September 11, 2026 | 1.868 |
| September 10, 2026 | 1.845 |
| September 09, 2026 | 1.877 |
| September 08, 2026 | 2.008 |
| September 04, 2026 | 2.119 |
| September 03, 2026 | 2.008 |
| September 02, 2026 | 1.973 |
| September 01, 2026 | 1.944 |
| August 31, 2026 | 1.985 |
| August 28, 2026 | 1.950 |
| Date | Value |
|---|---|
| August 27, 2026 | 2.008 |
| August 26, 2026 | 2.037 |
| August 25, 2026 | 2.078 |
| August 24, 2026 | 1.897 |
| August 21, 2026 | 2.043 |
| August 20, 2026 | 1.950 |
| August 19, 2026 | 2.043 |
| August 18, 2026 | 1.804 |
| August 17, 2026 | 1.815 |
| August 14, 2026 | 1.845 |
| August 13, 2026 | 1.932 |
| August 12, 2026 | 1.920 |
| August 11, 2026 | 1.956 |
| August 10, 2026 | 1.920 |
| August 07, 2026 | 1.880 |
| August 06, 2026 | 1.856 |
| August 05, 2026 | 1.850 |
| August 04, 2026 | 1.932 |
| August 03, 2026 | 1.856 |
| July 31, 2026 | 1.751 |
| July 30, 2026 | 1.775 |
| July 29, 2026 | 1.734 |
| July 28, 2026 | 1.780 |
| July 27, 2026 | 1.757 |
| July 24, 2026 | 1.728 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Editas Medicine, Inc. | 3.821 |
| Amgen, Inc. | 18.64 |
| Halozyme Therapeutics, Inc. | 87.28 |
| Novavax, Inc. | -- |
| AVITA Medical, Inc. | -- |
Price to Book Value Related Metrics
| PS Ratio | 38.22 |
| Price | 4.12 |
| Earnings Yield | -25.15% |
| Market Cap | 2.201B |